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Drug resistance mechanisms in renal cell carcinoma (RCC) still remain elusive. Although
most patients initially respond to targeted therapy, acquired resistance can still develop
eventually. Most of the patients suffer from intrinsic (genetic) resistance as well, suggest-
ing that there is substantial need to broaden our knowledge in the field of RCC genetics.
As molecular abnormalities occur for various reasons, ranging from single nucleotide poly-
morphisms to large chromosomal defects, conducting whole-genome association studies
using high-throughput techniques seems inevitable. In principle, data obtained via genome-
wide research should be continued and performed on a large scale for the purposes of drug
development and identification of biological pathways underlying cancerogenesis. Genetic
alterations are mostly unique for each histological RCC subtype. According to recently pub-
lished data, RCC is a highly heterogeneous tumor. In this paper, the authors discuss the
following: (1) current state-of-the-art knowledge on the potential biomarkers of RCC sub-
types; (2) significant obstacles encountered in the translational research on RCC; and (3)
recent molecular findings that may have a crucial impact on future therapeutic approaches.
Keywords: genomics, personalized treatment, prognostic and predictive biomarkers, high-throughput techniques,
genome-wide analysis, translational research, renal cell carcinoma, tumor heterogeneity
INTRODUCTION
Among solid urological tumors, renal cell carcinoma (RCC) has
the highest death rate. About 40% of patients with this condition
do not survive. Moreover, symptomatic metastases are observed
in 33% of the cases at diagnosis. The morbidity of RCC constantly
increases by about 1.5–5.9% annually, but due to the develop-
ment of new non-invasive diagnostic methods, this increase is not
rapid. However, this tumor remains the 10th most common in
men and 14th most common in women. Consequently, it is still
perceived as a serious disease that can affect the entire population,
also children (1).
Kidney cancers are mostly of sporadic origin, but some patients
are genetically predisposed, suffering from von Hippel-Lindau
(VHL) syndrome, which is connected with the loss of the VHL
suppressor gene function (VHL follows an autosomal dominant
hereditary pattern) (2). Around 40–60% of patients with mutated
VHL suffer from clear cell renal cell carcinoma (ccRCC). Other
RCC subtypes are comprised (according to the World Health
Organization system) of the following: (1) renal oncocytoma;
(2) papillary renal cell carcinoma (PRCC); and (3) chromophobe
renal cell carcinoma (chRCC). They may also comprise recently
recognized rare malignancies, such as (4) collecting ducts of Bellini
renal cell carcinoma (cdRCC); (5) renal medullary carcinoma; (6)
renal carcinoma associated with the translocation of locus 11.2 on
the short arm of the X chromosome; and (7) mucinous tubular
spindle cell carcinoma (3, 4).
von Hippel-Lindau syndrome was first shown by German oph-
thalmologist Eugen von Hippel,who described angiomas in the eye
in 1904 (5). Subsequently, Arvid Lindau described the angiomas
of the cerebellum and spine in 1927 (6, 7). The term“VHL disease”
was first used in 1936; however, its use became common only in
the 1970s. Since 1926, almost 400 cases of VHL disease have been
reported in the literature (4). VHL mutation was observed in renal
cell carcinoma inter alia by Seizinger et al. in 1988. Their article
was published in Nature (3). The authors confirmed that the dis-
order followed an autosomal dominant inheritance pattern and
that it predisposed to cancerogenesis.
Later on, VHL gene was shown to be located on the short
arm of the third chromosome (3p25), which also mapped the
locus encoding RAF1 (v-raf-1 murine leukemia viral oncogene
homolog). As sporadic forms of RCC have previously been
associated with the loss of specific regions of chromosome
3p, this information was crucial (4). Additionally, the active
form of the RAF1 oncogene has a significant impact on the
protein synthesis in the RAS/mitogen-activated protein kinase
(MAPK) signaling pathway (8). The latter transmits chemi-
cal signals from outside the cell to its nucleus. It also con-
trols cell growth, proliferation, differentiation, migration, and
apoptosis (8).
In 1990, Hosoe et al. performed genetic linkage analysis on
families with VHL. This complex study took almost 10 years to
complete and it resulted in the fundamental identification of
many mutations in 1998 (9). However, the first signs that VHL
may be connected with kidney cancers in general were reported
in 1979 by Cohen et al., who published a report about a single
family, some members of which were presented to have bilateral
multifocal ccRCC connected with the translocation of chromo-
some 3 (9). This gene was attributed only to ccRCC, since VHL
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mutations are not found in papillary, chromophobe, collecting
duct, or medullary renal cancer (10–13).
It is worth noting that VHL protein is a substrate of E3 ubiq-
uitin protein ligase complex. It is also the main regulator of the
hypoxia inducible factor (HIF) (mainly 1-α and 2-α; the role of
HIF3-α is unknown). E3 binds α subunits, leading to their ubiqui-
tination and further degradation (14, 15). The role of HIF subunits
in kidney cancer will be described in detail later.
Up to 40% of sporadic ccRCCs have a wild-type form of VHL
(non-mutated). This leads to the assumption that ccRCC is a dis-
ease of many mutations and is, therefore, highly heterogeneous
(16). Renal cell carcinoma is now perceived as a heterogeneous
cancer in general (17). There are many known RCC subtype-
dependent genetic alterations up to date. These include the SET
domain containing protein 2 (SETD2), PBMR1, and BAP1 genes,
which will be mentioned and described in later chapters.
The increasing frequency of conducting genetic research shows
that a wide variety of methods concerning the fast identifica-
tion of genetic and epigenetic RCC disorders exist. Currently,
researchers use more precise methods, especially comparative
genomic hybridization (CGH), high-resolution CGH and array
CGH, as well as whole-genome arrays. Only detailed genomic
analyses allow the complex description of genetic alterations in
renal cell carcinoma and the linking of tumorigenic changes in
the kidney with genetic alterations on a global level. This review
shows why high-throughput techniques used in genomic studies
may become the first step toward personalized treatment in renal
cell carcinoma (16, 17).
In this review, authors aim to prove that RCC is a heteroge-
neous tumor and harbors several mutations characteristic only
for each particular subtype of this cancer. This will be described
in the first chapter. Secondly, it will be shown that RCC is a potent
target to seek for potential diagnostic, prognostic, and predictive
biomarkers, which may solve many problems that currently clini-
cians have to face. The authors will also present some results in this
matter, which are promising and may lead to further classification
of specific molecular RCC patterns. Furthermore, the authors will
present evidence that those mutations are significant components
of crucial signaling pathways leading to cancerogenesis and metas-
tases. On the other hand, the authors will raise significant critical
questions concerning renal cell carcinoma and they will seek for
an answer, whether genomic analysis really is more promising
in RCC than in other cancers and why it is necessary to con-
duct more experiments on the genomic level in this field. Finally,
after discussing the current state-of-the-art in RCC personalized
treatment, the authors will conclude on to which extent RCC per-
sonalized treatment is possible and whether genomic studies still
have potential to broaden the knowledge of molecular oncologists
and in the end clinicians as well, to implement it in everyday life.
RCC IS A GENOMIC DISEASE AND IT HARBORS UNIQUE
MUTATIONS DEPENDENT ON ITS HISTOLOGICAL SUBTYPE
According to Larkin et al., renal cell carcinoma is widely defined as
a “constellation of malignancies of different histological subtypes
arising from renal parenchyma” (16). This means that patients
with RCC exhibit different sets of mutations depending on what
histological subtype of RCC they suffer from.
CLEAR CELL RCC
The most common RCC subtype, ccRCC possesses several dis-
tinct genetic alterations. These include the previously mentioned
loss of function of the VHL tumor suppressor gene, inactiva-
tion of the SET domain containing protein 2 (SETD2), KDM6A,
KDM5C – both lysine (K)-specific demethylases – and poly-
bromo1 (PBRM1). These genes are mentioned together because of
their common function; they are all chromatin remodeling com-
plex genes (15). Chromatin remodeling means dynamic chromatin
modifications in its construction, which enables various transcrip-
tion factors to be selectively attached to the condensed structure
of DNA. This is achieved through several various histone mod-
ifiers (17). Knowledge regarding this matter has been acquired
through the large-scale sequencing of ccRCC tumors. Polybromo1
has been found to be mutated in ~40% of cases, being the second
most mutated gene in ccRCC after VHL. Knowing this, it is eas-
ier to target this molecule if it is a specific target in the ccRCC
treatment (17).
More recently, BRCA related-protein 1 (BAP1) has been
reported in 4% of 98 ccRCC samples (18). In addition, SETD2
(mutated in 8% of cases) was found to be located on the short
arm of the third chromosome (like PBMR1) close to the specific
locus of VHL. SETD2 was a histone methyltransferase and BAP1
was its deubiquitinase. Both were involved in the remodeling of
the chromatin. The relation between these three genes has been
studied by Hakimi et al. in the previous year (19). In the study,
targeted sequencing was conducted in 185 ccRCC cases. Apart
from the significant percentage of mutations of the three genes
mentioned above, KDM5C was also shown to be mutated in 8%
of the cases (19). A study of 145 patients with developed ccRCC
reported that in those harboring BAP1 and PBMR1 mutations, the
overall survival (OS) rate was significantly shorter than in patients
harboring only PBMR1 mutation. It is worth noticing that those
results have been validated in a cohort from the Cancer Genome
Atlas study (20, 21).
Among other genes, hypoxia-inducible factors are significant
in ccRCC. They are inhibited by the functional protein of the
VHL gene under normoxic conditions via the polyubiquitination
process (it is known that it concerns HIF-1α). If lack of oxygen
occurs (hypoxia is a natural condition in most tumors), HIF-1α
is not degraded; therefore, it accumulates and binds to a stable
β-subunit of HIF-1. In consequence, HIF genes are activated, reg-
ulating angiogenesis. As a result, new vessels are excessively formed
to “feed” the tumor. This phenomenon is characteristic of ccRCC
and has been proven by various genomic research (22–24).
Taking these data together, it may be assumed that ccRCC pos-
sesses its own distinctive mutations in its genetic profile. In the
study of Zhang et al., wherein cytogenetic profiles of four RCC
tumor subtypes have been compared, −3p, +5q, and −8p have
been perceived as unique to ccRCC tumors (25). What is more,
research by Pei et al. (26) using both classical cytogenetics as well
as microarray-based genomic copy-number analysis has revealed
several similar rearrangements in ccRCC. SNP-based arrays per-
formed by this scientific group showed the deletion of 3p in 16 out
of 20 tumors (80% cases) (26).
Summing up, VHL gene is a key factor, mostly because of
the following reasons: (a) it often predisposes patients with VHL
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syndrome to develop hereditary ccRCC; (b) it is the most com-
mon alteration in sporadic ccRCC; and (c) it is found even in
small ccRCCs at early diagnosis (26).
PAPILLARY RCC
The hereditary form of PRCC (HPRCC, type I PRCC) also has
its specific proto-oncogene: MET. Schmidt et al. first performed
genetic linkage analysis on this type of cancer in 1997. Muta-
tions of MET proto-oncogene have been noticed in its tyrosine
kinase domain, which has classified HPRCC for targeted ther-
apy against MET and vascular endothelial growth factor (VEGF)
receptors (27). Two years later, the same scientific group reported
that hereditary PRCC was characterized by multiple, bilateral
papillary renal carcinomas. They also screened a large group of
sporadic papillary renal carcinomas and many other solid tumors
for various mutations in MET proto-oncogene. Summarizing
these and the previous results, they have presented such muta-
tions in 17 out of 129 sporadic papillary renal carcinomas, but
not in other solid tumors. What was striking was that even in
1999, molecular modeling studies suggested the importance of
activating mutations. It was known that such phenomena tended
to facilitate transition to the active form kinases, in this case MET
kinase, leading to the formation of a different histological RCC
subtype (28).
Type II papillary kidney cancer has been described in litera-
ture along with “hereditary leiomyomatosis renal cell carcinoma
(HLRCC),” which also has its characteristic gene – the fumarate
hydratase coding gene. If a specific mutation disables the FH gene,
the Krebs cycle would be modified, favoring the excessive synthe-
sis of fatty acids, which in turn promotes tumor growth (Warburg
effect) (29).
CHROMOPHOBE RCC
A hereditary form of chromophobe renal cancer also exists. It
is called the Birt-Hogg-Dubé (BHD) disease. In this condition,
patients usually develop bilateral, multifocal renal tumors, fibrous
folliculomas, and/or pulmonary cysts. This type of disease is more
complex than other kidney cancers. Patients with VHL develop
ccRCC, while patients with HPRC develop type 1 papillary kidney
cancer. However, patients suffering from BHD tend to develop
a spectrum of renal tumor subtypes, including chromophobe,
clear cell, oncocytomas, or hybrid oncocytic tumors (30). BHD
has turned out to be connected with the folliculin-coding gene
(FLCN) mutation. Generally, it is perceived as a tumor suppressor
as its several types of mutations lead to various tumor formations.
Vocke et al. have identified folliculin mutation in about 70% of
patients in the research probe (31). It should be noted that this
gene belongs to the LKB1/AMPK signaling pathway. The protein
encoded by FLCN leads to several processes, including the binding
of protein FNIP1, FNIP2, and gamma subunit of AMPK, an AMP-
activated protein kinase. As the LKB1 tumor suppressor kinase
is an activator of the AMPK, it forms a number of cellular ener-
getic levels by favoring either catabolic or anabolic processes. It is
known that this pathway controls, among others, cell polarity. The
molecular link between such polarity and metabolism may result
in a stress-response protective mechanism, which in turn leads to
tumor suppression during evolution (32–34).
The proper diagnosis of kidney cancer subtypes is becoming
more and more complicated and difficult to achieve after the recog-
nition of novel RCC subtypes. Owing to this, several researches
in oncology focused on the assessment of the potential diagnos-
tic possibilities of gene-expression profiling to serve as a more
specific follow-up to the histopathological examination in con-
troversial RCC cases. Different platforms have been used until
now, including cDNA microarray (clones), Affymetrix technology
(probe sets, genes), and nylon cDNA microarray (clones) (35–43).
It has to be understood that although most of these studies dif-
fer much in terms of their methodological concept, their most
significant findings coincide. For example, the gene most often
up-regulated in hypoxia conditions and in the presence of VHL
mutation is cyclin D1 (44).
Although the identification of genetic changes – as a result of
advanced genomic studies – is undoubtedly a step forward toward
personalized medicine in RCC, it should be noted that the exact
and detailed role of most of these mutations still remain unclear.
Subsequently, targeting these mutations could lead to many diffi-
culties. However, such studies should be continued as there may
still be other RCC subtypes waiting to be discovered.
POTENTIAL PREDICTIVE AND PROGNOSTIC RCC
HISTOLOGICAL SUBTYPES BIOMARKERS AND THEIR
DESCRIPTION
Molecular biomarkers are currently defined by the National Insti-
tute of Health Biomarkers Definitions Working Group (45). This
organization was founded primarily to address the rapid expan-
sion of gained (mainly genomic) data in the field of the diseases’
molecular basis (39). Ngo et al. have searched through PubMed for
the phrase “renal cell carcinoma and biomarker” and have initially
found over 3000 publications (46). Nonetheless, not all of those
that came up in the search were really essential. It is known that,
there are no standard approaches that can be used in biomarker
sampling or in the analysis of kidney cancer. There are techni-
cal problems to be faced as well. For example, blood biomarkers
are extremely vulnerable to many degradation processes (such as
proteases, nucleases, and so forth).
Out of 48 studies analyzed by the Funakoshi scientific group,
only three have satisfied Level 1 evidence for progression-free sur-
vival (PFS) in RCC. None of these is commercially produced in the
market. These three are interleukin-8 (IL-8), hepatocyte growth
factor (HGF), and osteopontin (47). This means that at present,
no RCC biomarker is a fully credible candidate for use in clinical
practice.
In the current literature, information on the definitions of the
terms“prognostic”and“predictive”may sometimes be misleading.
A prognostic biomarker is a biomarker that possesses a minimum
of one clinical or biologic, objectively measurable characteristic.
At the same time, a prognostic biomarker provides information on
the probable outcome of a specific disease (in this case, renal cell
carcinoma) in an untreated patient. Prognostic markers are widely
used to identify individuals with cancer and who are at high risk of
developing metastases. These markers also may serve as potential
candidates for adjuvant therapy. On the other hand, there are pre-
dictive factors that show the patients the probable benefits they can
obtain from the treatment. Significantly, prognostic factors pertain
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to the effects of the tumor characteristics on patients. Predictive
factors, on the other hand, pertain to the effects of treatment on
the tumor (48).
Contemporarily, there are several main methods used to per-
form mRNA expression profiling on the entire genome scale.
These range from gene-expression microarrays or gene-expression
serial analysis to differential display. With regard to array plat-
forms, they may consist of purified cDNAs (spotted) or oligonu-
cleotides (mostly photolithographic) (44). Some examples of
genomic research in the field of renal cell cancer biomarkers will be
described below. Gene-expression microarrays concerning RCC
have also been successfully used to seek for immunomarkers as
well (49).
Garraway et al. (50) has predicated a few key principles that
may underlie translational cancer research and serve as a guide
to the genomics-driven RCC research. One of them states that
“molecular pathways involved in tumor survival and progression
are often enacted by genetic alterations” (50). This is true in the
case of the specific histological subtypes of renal cell carcinoma.
It should be noted that there is no universal molecular marker for
RCC. However, a few large genome-wide associated studies have
shown recently that some nucleotide polymorphisms (SNPs) exist
and that they may increase the patients’ risk of developing renal cell
cancer. Some authors have meta-analyzed gene-expression arrays;
others have conducted studies themselves. Each time these authors
identify susceptibility loci (2p21, 11q13.3, 12p11.23, etc.) (51–54),
which often show the high importance of such array studies, they
provide molecular prognostic tests for future patients.
In 2007, Dalgin et al. performed a high-throughput microarray
analysis on the RCC gene-expression profiles in order to specify the
characteristics of the molecular markers of each histological sub-
type. Specific tumor markers were proposed by his scientific team.
Microarray analysis was a key process in this field. Among 158
genes, ATPase, H+ transporting, lysosomal 56/58 kDa, V1 subunit
B1 (ATP6V1B1); egl-9 family hypoxia-inducible factor-3 (EGLN3),
Solute Carrier Family 25 [SLC25A5 (adenine nucleotide transloca-
tor), Member 51], and beta-tubulin (TUBB), have been confirmed
to be crucial (30). However, in similar studies, new genes have been
also found to be important in RCC. These genes are all related
to the critical processes underlying kidney cell transformation.
Some of them are involved in excessive angiogenesis, escape from
apoptosis, and cell adhesion or proteolysis (54).
Gene-expression profiling has unfortunately been somewhat
limited to ccRCC, distinguishing its typical mutations, alter-
ations, and biomarkers on the basis of genome-wide research. For
instance, Dondeti et al. have performed an integrated analysis of
such data for 54 sporadic ccRCCs and, as a result, they have iden-
tified the secreted glycoprotein stanniocalcin 2 (STC2) and the
proteoglycan versican (VCAN ) to serve as potential oncogenes in
ccRCCs. Both are located on the long arm of the fifth chromosome.
In their functional assays, STC2 and VCAN were shown to pro-
mote cell survival (55). Older research was carried out in 2001 by
Takahashi et al., who performed pioneering studies at that time to
better understand the molecular mechanisms underlying ccRCC
progression (56). This scientific group studied the gene-expression
profiles of 29 ccRCC tumors by using 21,632 cDNA microarrays.
As a result, alterations dedicated to most of the studied ccRCCs and
which were unique to clinical subsets were also defined (cerulo-
plasmin, kininogen, lysyl oxidase, and the now well-known VEGF)
(57). Later studies confirmed these results (58–60).
In another study on ccRCC biomarker candidates (61) with an
integrated analysis of copy-number and expression profiles, the
authors proposed 22 significantly overexpressed genes compared
to those in healthy kidneys. Twelve of them were judged as proto-
oncogene candidates in ccRCC with the use of high-throughput
techniques. What is interesting is that they were also located in
locus 5q35.3, apart from the constantly overexpressed gene on the
long arm of the eighth chromosome, which is MYC (data fur-
ther confirmed) (61). Many other mutations have been reported
to be unique for ccRCC and such results have been obtained
mostly via detailed genomic analyses or even large-scale sequenc-
ing. It is hard to mention them all in this article because of their
large number (61–67), which only underlines the significance of
high-throughput research in this field.
Another study performed by Schmidt et al. in 1997 comprising
the genetic linkage analysis on hereditary papillary RCC. Muta-
tions of MET proto-oncogene were shown to be present in its
tyrosine kinase domain, which has classified HPRC for targeted
therapy against MET and VEGF receptors (27). Two years later,
the same scientific group reported that hereditary PRCC was char-
acterized by multiple, bilateral papillary renal carcinomas. They
also screened a large group of sporadic papillary renal carcino-
mas and many other solid tumors for various mutations in MET
proto-oncogene. Summarizing these along with previous results,
they presented such mutations in 17 out of 129 sporadic papillary
renal carcinomas, but not in other solid tumors. What is striking
is that even in 1999, molecular modeling studies suggested the
importance of activating mutations and it was known that such
phenomena tended to facilitate the transition to the active form
kinases, which, in this case was MET kinase, leading to the for-
mation of a different histological RCC subtype (27, 28). This was
an example of early genomic approaches geared toward defining
hereditary papilloma RCC biomarkers.
In 2013, a significant paper on DNA methylation profiling was
published (28). DNA hypermethylation has been used to show
distinctive profiles of chromophobe RCC and renal oncocytomas
(5% cases). The authors utilized the Infinium Human Methylation
450 Beadchips technique. They identified 30 hypermethylated and
41 hypomethylated genes, differing its expression between chro-
mophobe RCC and renal oncocytomas (p< 0.05), which could
easily stand for a reliable histological biomarker after utilization
in the future (34).
Currently, there is one more promising biomarker in RCC diag-
nosis – the interleukin 6 (IL-6) (48). IL-6 does not only play a
significant role in systemic inflammation, but it also has a serious
impact on the angiogenesis and signal transducer and activator
of transcription 3 (STAT3). Renal cell carcinoma is known to
produce excessive levels of IL-6 compared to other tumors (68).
Unfortunately, IL-6 still has not fulfilled the minimum of Level I
evidence for outcome prediction. There is a need to conduct fur-
ther genomic research on this matter especially that up to now,
IL-6 has only been revealed as a result of the ELISA tests (48).
The most important and promising among the up-to-date RCC
biomarkers (both predictive and prognostic) are presented in
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Table 1 | Chosen RCC prognostic and predictive biomarkers, which have been discovered as a result of high-throughput genomic research
conducted up to date.
Candidate RCC
biomarkers – type
Candidate RCC biomarkers – name High-throughput method used Reference
Predictive VEGFR-3 polymorphism rs307826 SNPs (Single nucleotide polymorphisms), genotyping Garcia-Donas et al. (70)
IL-8 phenotype 276TT SNPs, genotyping Xu et al. (71)
HIF-1αa phenotype 1790AG RNA microarray Choueiri et al. (72)
VHL mutation/methylationa DNA sequencing Garcia-Donas et al. (70)
OPN Multiplex bead array Zurita et al. (73)
VEGF a Multiplex bead array Zurita et al. (73)
TRAIL Multiplex bead array Zurita et al. (73)
VEGFR-2 Multiplex bead array Zurita et al. (73)
MET Comparative genomic microarray analysis (CGMA) Albiges et al. (74)
CXCR7 Gene-expression analysis of TECs Maishi et al. (75)
PD-0332991 Array comparative genomic hybridization (CGH) and
gene expression
Logan et al. (76)
Prognostic miR21/10b ratio Deep sequencing data from TCGA datasets Fritz et al. (77)
(HIC1) CpG island methylation Pyrosequencing Eggers et al. (78)
VEGFR-3, vascular endothelial growth factor-3; IL-8, interleukin-8; HIF-1α, hypoxia-inducible factor 1α subunit; VHL, von Hippel-Lindau; OPN=SPP1 secreted phos-
phoprotein 1; TRAIL, tumor necrosis factor-related apoptosis inducing ligand; MET, mammalian target of rapamycin; CXCR7, chemokine (C-X-C motif) receptor 7;
PD-0332991, palbociclib, inhibitor of cyclin-dependent kinase 4/6; miR, micro RNA; HIC1, hypermethylated in cancer 1.
aBiomarkers are attributed either to the “predictive” or “prognostic” candidates on the basis of the information obtained from the current literature (if a biomarker is
more often cited in PubMed as “predictive” – it is attributed to the “predictive” group).
Table 1 along with the genomic techniques used to find them.
It has to be strongly noted that up to this day, none of the
potential biomarkers described above or presented in Table 1
have been validated for clinical use (68). Unfortunately, not all
research conducted in this matter are reproducible; therefore,
as Sonpavde and Choueiri state in their recent publication, the
utilization of the Clinical Laboratory Improvement Amendment
(CLIA) seems to be inevitable to enhance reproducibility. Hetero-
geneity and toxicity, described in further chapters, seem to be the
main challenge (69).
RCC GENOMIC STUDIES REVEALED IMPAIRED SIGNALING
PATHWAYS
Genomic studies tend to gather large amounts of data. Subse-
quently, pathway analysis has become a commonly used technique
in cancer research. Recent publications on the Gene Set Enrich-
ment Analysis (GSEA) technique have been published by Zeng
et al. (79). This method was first introduced in 2003 for other
tumor types; however, in this particular case, ccRCC was given
focus. Such computational technique, the main aim of which
was to define the specific features of signaling pathways rather
than individual genes, combined with a functional enrichment
set analysis tool, was shown to provide complete information on
crucial altered processes in ccRCC. Published this year, the study
comprises seven datasets with 110 ccRCC cases and 73 healthy kid-
ney samples as a control. The study resulted in the revelation of
17 down-regulated and 12 overexpressed genes. Most of the path-
ways revealed by the GSEA were immune system diseases pathways
(see: RCC genome and treatment), amino acids metabolic path-
ways, and carbohydrate metabolic pathways. The alterations of
the Janus kinase/signal transducers and activators of transcription
(JAK/STAT) signaling pathway (30 genes altered), as well as the
cytokine-cytokine receptor interaction pathway (50 genes altered)
(79, 80) were vital. The Database for Annotation, Visualization
and Integrated Discovery (DAVID) enrichment analysis system
was also used and it identified other important altered path-
ways in the ccRCC. These included the peroxisome proliferator-
activated receptor (PPAR) signaling pathway (22 genes up- or
down-regulated), ErbB signaling pathway (26 genes altered), and
the insulin signaling pathway (42 genes altered). It has to be noted
that due to the huge number of altered metabolic pathways, it was
possible that ccRCC was a metabolic tumor (79, 80). It should be
noted as well that this finding, if widely accepted by clinicians,
would radically change the therapeutic approaches used in many
of the ccRCC cases.
The JAK/STAT pathway is the main signaling mechanism for
a wide variety of cytokines and growth factors in mammals. Its
activation stimulates cell proliferation, differentiation, migration,
and apoptosis; therefore, it is crucial in the process of cancero-
genesis. The JAK-STAT pathway also transmits the information
received from extracellular signals (through the receptors located
in the membrane) straight to the target gene promoters in the
nucleus. This way, it provides mechanisms for transcriptional reg-
ulation without second messengers. The JAK-STAT is a highly
adapted, ligand-specific signaling pathway whose main function
is to strictly control gene expression. If JAK-STAT is deregulated,
gene over, or under-expression could take place (81, 82).
The PPAR signaling pathway is essential as well. PPAR-activated
receptors are nuclear receptor proteins that act as transcription
factors that regulate processes, such as the expression of genes,
cellular differentiation, development metabolism, and tumori-
genesis. It has recently been reported that TGF-beta1 induces
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epithelial–mesenchymal transition (proven to exist in ccRCC) in
NRK52E cells via SMAD and PPAR-γ pathway (83).
The ErbB protein family or epidermal growth factor receptor
(EGFR) family is a family comprising four structurally related
receptor tyrosine kinases. Pénzváltó et al. have performed a
research focused on identifying resistance mechanisms against
tyrosine kinase inhibitors (sunitinib, erlotinib, lapatinib, sorafenib,
and gefitinib at the clinically administered doses), targeting the
ErbB/RAS pathway in 45 cancer cell lines (also in renal cell carci-
noma, as this pathway was often targeted in the latest anti-RCC
therapy) (82).
Dalgin et al. (30) also revealed that the top-ranked pathways
with significant influence on RCC development included the
following: MAPK signaling pathway, G-protein coupled signal-
ing pathway (and others connected with metabolism), and the
immune response signaling pathway (30). Apart from MAPK, all
results from 2014 confirmed the results obtained in 2007 (42).
Mitogen-activated protein kinase is a crucial particle. It regulates
the activities of several transcription factors and phosphorylates
and activates the c-Myc or MNK (MAP kinase interacting ser-
ine/threonine kinase), which in turn phosphorylates the cyclic
adenosine monophosphate (cAMP) response element binding
protein (CREB). Mechanistically, by changing the activities of
various transcription factors, the mutations of MAPK can lead
to the altered transcription of genes that are significant to the cell
cycle (82).
With regard to the previously mentioned HIF subunits as well
as VHL gene, it should be noted that for RCC, there is a HIF/VHL
pathway that is mostly deregulated in one of its subtypes. Physio-
logically, the VHL gene is needed for HIF-1α degradation; there-
fore, in the case of VHL mutation (occurring in ccRCC), HIF-1α
is not properly degraded and is subsequently overproduced. Over-
production of this subunit leads to the increase in the binding
of HIF-1α to the so-called hypoxia responsive elements, which in
turn causes the over-expression of the VEGF. VEGF is also sig-
nificant in another crucial RCC pathway, the mammalian target
of rapamycin (mTOR) pathway (84). The mechanistic target of
rapamycin (serine/threonine kinase), mTOR is a protein encoded
by the mTOR gene, a serine/threonine protein kinase that reg-
ulates cell growth, proliferation, motility, survival, and protein
synthesis and transcription in humans. This pathway is named the
PI3K/Akt/mTOR pathway and is essential in targeted RCC therapy
concerning mTOR inhibitors (85). The detailed stages of these two
combined pathways are shown in Figure 1.
To sum up, many crucial signaling pathways are impaired in
renal cell carcinoma. Mostly, they are known in ccRCC. They
are mainly connected with cellular differentiation (leading to
tumorigenesis) or with altered metabolism. Research still needs
to be done to explain the real meaning and consequences of the
altered metabolism factor in the tumorigenic process of renal cell
carcinoma.
IS PERSONALIZED THERAPY REALLY POSSIBLE? THE ISSUE
OF TUMOR HETEROGENEITY
In a recent systematic review of English-language literature with
the use of the Preferred Reporting Items for Systematic Reviews
and Meta-analyses (PRISMA) criteria, it has been clearly stated by
Shuch et al. that contemporary understanding of renal cell carci-
noma origin should switch from a uniform-malignant-phenotype
model to a model in which heterogeneous group of cancers arise
from kidney’s tubules (86).
It has recently been announced that the phenomenon of het-
erogeneity plays an important role in kidney cancer (87). In a
recent study published this year, a new method called multi-region
exome sequencing was used. The research that used this novel
genomic tool revealed some substantial intratumoral heterogene-
ity in primary ccRCCs. This identification has significant potential
for the future understanding of kidney cancer evolution and for
developing effective therapies (87). In another review article pub-
lished this year by Bex et al., the authors brought attention to the
immunological heterogeneity of renal cell carcinoma microenvi-
ronment. Tumor heterogeneity is perceived nowadays as a key issue
in molecular oncology (88).
There are four types of genetic heterogeneity in tumors accord-
ing to Vogelstein et al. in their latest science publication (89). Each
type is significant from the practical point of view when it comes
to biomarker genomic research.
Intratumoral heterogeneity occurs among the various cells of
one tumor. This phenomenon has been observed for years in sci-
ence. Each time a cell divides, it acquires a specific amount of new
mutations. Consequently, it is almost impossible to observe two
genetically identical cells in one tumor (89). Lately, some stud-
ies have focused on the intratumoral heterogeneity evaluation
of a genome (90–93). These studies mostly used the genome-
wide sequencing technique. The common conclusion is that dif-
ferences are meaningless in primary tumors as patients mostly
undergo resection. Information obtained from such histopatho-
logical materials is crucial for understanding intermetastatic het-
erogeneity, especially among different metastatic lesions found
in one specific patient (89). An interesting and highly probable
hypothesis, which states that genetic mutations or other alterations
that condition metastases formation occur earlier than the actual
metastasis, has been proposed by Gerlinger et al. in 2012 (93).
There was also an intrametastatic heterogeneity among the cells
of one metastasis of a patient, as well as an interpatient hetero-
geneity among the tumors of different patients. It was known that
none of the oncologists had ever observed two genetically identical
patients presented with the same specific cancer subtype) (94).
It has been brought to our attention by authors of several
publications that most human cancers are caused by two to
eight alterations occurring one after another and which tend to
develop in the course of 20–30 years. During that time, formu-
lating tumor tends to become genetically divergent as excessive
cell division proceeds. Inevitably, genetic heterogeneity begins
to form. It is always present and always influences the patient’s
response to therapeutics; therefore, the most logical and most
simple approach would be to perform genome-wide studies on
the individual’s germline genome, along with the same research
on the tumor. Such method of prevention would be a significant
scientific achievement if successful (89, 91, 94).
Fisher et al. have already asked themselves a question, which
is addressed in this chapter: “Is such heterogeneity a barrier to a
personalized treatment in RCC?” Most probably, the concept that
the sub-populations of different cancer cells (or of other cells)
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FIGURE 1 | Hypoxia inducible factor andVEGF link the HIF/VHL and
PI3K/Akt/mTOR signaling pathways. Vascular endothelial growth factor,
together with other external growth factors, activates Akt, which in turn
activates mTORC1 complex The PI3K (phosphoinositide 3-kinase) pathway
may be overactive because of faulty or deficient phosphatase and tensin
homolog (PTEN ). mTORC1 is a protein complex that functions as a specific
controller of protein synthesis. It is composed of mTOR itself, a
regulatory-associated mTOR protein named Raptor, mammalian lethal with
SEC13 protein 8 (MLST8) and GβL, a positive regulator of the
rapamycin-sensitive pathway required for the nutrient-sensitive interaction
between Raptor and mTOR. What is striking is that it has been shown that
mTORC1 complex, when up-regulated, subsequently up-regulates the
expression of HIF-1α subunit (143–146).
Under conditions of lower oxygen tension (hypoxia), VHL tumor suppressor
protein becomes inactivated, which results in constitutive activation of the
HIF pathway. HIF protein is heterodimeric; it consists of two constitutively
expressed subunits: β-subunit and an oxygen-sensitive α-subunit. The latter is
not degraded in such conditions; therefore, it translocates to the nucleus.
Inside the nucleus, it undergoes dimerization with HIF-β subunit to form
transcriptionally active HIF. In consequence, HIF as a transcription factor
starts to regulate many biological processes via hypoxia-inducible genes, such
as: SDP1 (scan domain containing protein), GLUT1 (glucose-transporter 1),
LDH (lactate dehydrogenase), EPO (erythropoietin), ADM (adrenomedullin),
PDGFR-β (platelet-derived growth factor-β),TGF-α (tumor growth factor-α).
Other genes activated by mTORC1 complex: p70S6 kinase, 4E-BP1
(4E-binding protein 1), eiF-4E (eukaryotic translation initiation factor 4E)
(143–146).
Under conditions of normal oxygen tension (normoxia), HIF-α subunit is
hydroxylated by specific prolyl-hydroxylases and subsequently targeted for
rapid proteasomal degradation. This is done by the VHL tumor suppressor
protein, which is active at the time. In other words, HIF protein is degraded in
proteasome when prolyl-hydroxylated α-subunits are targeted to the process
of ubiquitination. It occurs by high-affinity binding to the VHL E3 ubiquitin
ligase. Tumorigenic processes do not occur (147, 148).
significantly affect the research and treatment of RCC is true. The
most important problem concerns metastatic lesions. In reality, it
is practically impossible to design a unique drug therapy for each
individual patient despite ongoing research in the field of RCC
biomarkers (95). There is no prognostic or predictive RCC bio-
marker for everyday use. It may be assumed that heterogeneity
in RCC may significantly reduce the effectiveness of biomarker
research. There is a need to improve and upgrade genomic studies
to overcome difficulties or even find other possible ways to over-
come the problem of heterogeneity using the knowledge of cancer
genomics. The key step for researchers and clinicians and, most
of all for patients, is the diagnosis. Early detection (in the first
10% of the cancer’s life span) almost guarantees 100% curabil-
ity. Strong scientific, financial, and organizational efforts must be
done to overcome the problem of heterogeneity to make RCC bio-
markers enter the worldwide market (89). As microarray analyses
have already resulted in the discovery of novel immunohistochem-
ical markers, and several other markers have been validated to
some extent (see Potential Predictive and Prognostic RCC Histo-
logical Subtypes Biomarkers Description), continuing this work
is obligatory for combining such markers into specific diagnostic
panels.
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CURRENT STATE-OF-THE-ART AND RECENT
BREAKTHROUGHS IN RCC GENOME AND TREATMENT
Gene-expression profiles have been proven to be useful tools
in identifying subtypes of cancer and in predicting outcomes.
Prognostic and predictive biomarkers are currently under intense
investigation. However, at this point in time, no validated gene-
expression signatures for RCC are being used in everyday practice
(96). Renal cell carcinoma, as a disease, lacks clinically applicative
and validated predictive biomarkers for the most active therapeutic
compounds, both targeting the mTOR (everolimus, temsirolimus)
and the VEGF pathways (sunitinib, axitinib, pazopanib, sorafenib)
(97). In some publications, the gene-expression profile has been
judged as a poor predictor of disease free survival (DFS) or
relapse/recurrence-free survival (RFS) (98).
A useful genomic tool in clinical RCC application, the 34-
gene classifier (ClearCode34) has been developed and enabled
lately to classify ccRCC tumors into two subtypes – referred
to as ccA and ccB – with different RFS, cancer-specific sur-
vival (CSS), and OS (99). With the use of ClearCode34, the
ccB subtype was characterized by the over-expression of var-
ious genes, including the Serpin Peptidase Inhibitor, Clade A
Member 3 (SERPINA3), Solute Carrier Family 4 Member 3
(SLC4A3), Monooxygenase, DBH-Like 1 (MOXD1), Potassium
Intermediate/Small Conductance Calcium-Activated Channel,
Subfamily N, Member 4 (KCNN4), Receptor tyrosine kinase-
like orphan receptor 2 (ROR2), Forkhead box M1 (FOXM1),
and the UDP-N -acetyl-alpha-d-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 4 (GALNT4) gene. Hazard ratios
(HR) for different ccRCC subtypes were similar to those in the
clinical stage and grade in association analysis with recurrence
risk. The HR for ClearCode34 remained significant in multivariate
analysis as well. This gene-expression-based model was shown to
be a better predictor for cancer-specific-survival compared to the
widely used University of California, Los Angeles Integrated Stag-
ing System (UISS or UI), and Mayo Clinic Stage, Size, Grade, and
Necrosis (SSIGN or SS) scores. ClearCode34 has demonstrated
the superiority of the molecular model over the standard clinical
predictive algorithm (99).
A novel gene-expression-based survival predictor was also pub-
lished as a result of an even more advanced gene-expression analy-
sis, which has covered nephrectomy cancer tissues obtained from
177 ccRCC patients. As a result, 259 genes were shown to accurately
predict disease-specific survival (DSS) independently during the
tumor stage, grade, and performance status. The authors of this
research belonged to the Eastern Cooperative Oncology Group
(ECOG). In the same analysis, the over-expression of 12 genes
was associated with a shorter OS. These genes included the BCL2-
Associated Athanogene 2 (BAG2), Guanine Nucleotide Binding
Protein Alpha Stimulating Activity Polypeptide Secretogranin
Complex Locus (GNAS), Immunoglobulin lambda constant 2
(IGLC2), and the Neutrophil cytosolic factor 1 (NCF1) (57).
Methodologically advanced genome-wide analyses were also
performed in cases where tissues from primary RCC tumors and
metastases were analyzed (94, 95). Pulmonary metastases that
developed synchronously and metachronously were included in
these analyses as well. Metastases had different expressions of 167
genes when compared to primary tumors. At the same time, 36
genes were shown to be differentially expressed when synchro-
nous and metachronous metastases were compared (97, 98). In the
study, gene-expression differences in the tumor and adjacent nor-
mal tissues from 93 patients have been detected using a genome-
wide expression array. A panel of 661 inflammation-related genes
was also analyzed. Consequently, various expression patterns
between tumor and normal tissues were identified (97, 98).
This study was very important from the clinical point of
view. The association of specific gene-expressions changed with
the recurrence of the tumor and survival was evaluated on the
mRNA and protein level. Prognostic significance was confirmed
at the mRNA level for CD31 (PECAM=Platelet/Endothelial Cell
Adhesion Molecule 1), Endothelin receptor type B (EDNRB), and
Tetraspanin 7 (TSPAN7 ). It was also confirmed at the protein
level for TSPAN7. Patients with an over-expression of EDNRB and
TSPAN7 had significantly longer DFS and CSS. Patients with over-
expressed CD31 had longer CSS only. In a multivariate analysis,
only the EDNRB over-expression was confirmed as an indepen-
dent prognostic biomarker of DFS. However, it is still not used in
clinical practice, despite the fact that the over-expressions of CD31,
EDNRB, and TSPAN7 were defined as independent prognostic
biomarkers at the CSS level (98). This analysis confirmed that the
comparative analysis of tissues from the primary tumors and the
metastatic samples may help to identify new prognostic biomark-
ers for RCC patients. The gene expression of the endothelial cells
from the tumor samples should also be incorporated into future
research so that there would be more possibilities of comparing
the results with additional research control groups (98).
There are several other examples of genome-wide analysis con-
cerning matters of RCC treatment. Recently, samples from 101
ccRCC patients have been used to identify genes that were differ-
entially expressed in cancer tissues as opposed to paired adjacent
normal tissues. Gene-expression data were used to identify bio-
markers that were independently associated with OS. Statistical
data covered the variables of age, sex, tumor grade, presence of
synchronous or metachronous metastases, gene expression, and
OS. This project identified eight genes, the over-expressions of
which were associated with favorable ccRCC prognosis, one of
which was epidermal growth factor receptor 5 (EGFR5) (100). In
another trial, the over-expression of survivin (BIRC5) was shown
to be associated with shorter CSS (101). A subsequent small study
of 29 patients showed that the over-expression of 40 genes was a
significant predictor of longer DFS and OS. The latter study dif-
ferentiated between cohorts with 100% 5-year survival rate and
patients with an average OS of 25.4 months and 0% 5-year sur-
vival rate (57). It was clearly visible that genomic research could
produce valuable data in the clinical field concerning RCC as well.
Inflammation-related gene-expression profile was defined as
a prognostic biomarker for the risk of ccRCC recurrence (for
GADD45G: growth arrest and DNA-damage-inducible, gamma
gene) and ccRCC death (for CARD9 : caspase recruitment domain
family, member 9, CIITA: class II, major histocompatibility com-
plex, transactivator, and NCF2: neutrophil cytosolic factor 2 genes)
(102). This was another example of the favorable use of genomic
research as a method of choice in clinical applications. In this
analysis, biological materials from 93 patients were analyzed using
the genome-wide expression array, which included a large panel
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of 661 inflammation-related genes. Gene expression in the tumor
was compared to the gene expression in the adjacent normal tis-
sues. In the second step, the association of the gene expression
with ccRCC recurrence (RR) and/or survival (OS) was analyzed.
Among them, 151 genes that were differentially expressed with
at least a twofold change were up-regulated in the tumor tis-
sues. Of these genes, 20 were found to be significantly correlated
with RR and/or OS. The over-expression of six genes, including
the amyloid-β precursor, was associated with a prolonged period
of recurrence (possible protective effect), referred to as a signifi-
cant decrease in the recurrence risk (RR). At the same time, the
over-expression of 12 other genes was associated with increased
recurrence risk. These genes that were of high expression and that
were associated with a higher risk of recurrence and shorter RFS
included the B-cell linker, CXCL1 [chemokine (C-X-C motif) lig-
and 1-melanoma growth stimulating activity, alpha], superoxide
dismutase 2, cell surface associated mucin 1, and CARD9. In partic-
ular, the over-expression of GADD45G increased the RR by 2.09-
fold while the risk of death was increased and OS was decreased
alongside with the over-expression of CARD9 (2.52-fold), NCF2
(2.26-fold), and CIITA (2.11-fold). CXCL1 over-expression was
shown to result in the increased RR by 7.08-fold and in more
than 30-month survival shortening. The most significant associ-
ation for the increased risk of death was found in the adenosine
A3 receptor (ADORA3) (HR 21.34) over-expression (102). On the
other hand, for the interleukin 2 (IL-2) and IFN-α combination
therapy, the over-expression of 14 genes was shown to predict a
good response rate. Those genes included the HLA genes and the
genes associated with immunological response, natural immunity,
and cytokine expression (8, 103, 104).
Whole-genomic analysis was also used for treatment success.
The analysis carefully covered the five selected patients with
metastatic ccRCC and who were treated with mTOR inhibitor
(everolimus or temsirolimus). This achieved a prolonged duration
of stable disease (SD). This SD was greater on the rapalogs than
on (first-line) the VEGF-targeted therapy (TKI). Patients with a
median duration of 28 months were included in the study. Adja-
cent normal kidney tissue obtained at nephrectomy was used as
control. DNA from tumors that matched normal tissues was ana-
lyzed using Illumina HiSeq 2000. In each individual patient, at
least two regions from the same primary tumor were analyzed. If
possible, a tumor tissue from a distant metastasis was also investi-
gated. In this analysis, significant heterogeneity between primary
and metastatic tumor and within a primary tumor was found. Ben-
efit for the mTOR treatment was applied to functional alterations
in two genes, namely, tuberous sclerosis 1 (TSC1) and mammalian
target of rapamycin complex 1 (mTOR1) (96). Intratumoral het-
erogeneity was recently confirmed through gene-expression signa-
tures. Good and poor prognosis were detected in different regions
of the same tumor, but not in the same patient. This report also
pointed to the activation of the mTOR kinase activity as significant
for tumor growth and clonal evolution (93).
The European Union multi-disciplinary Personalized RNA
interference to Enhance the Delivery of Individualized Cyto-
toxic and Targeted therapeutics (PREDICT) consortium started
its activity in the ccRCC field over the last 5 years. This project
was aimed at identifying the predictive biomarkers of sunitinib
and everolimus treatment (96). To reach the objectives, two
neo-adjuvant clinical trials were designed. These were the (1)
S-PREDICT/PREINSUT for the sunitinib cohort and the (2) E-
PREDICT for everolimus. The S-PREDICT/PREINSUT – biolog-
ical, pathological, and imagery markers in the first-line treatment
of metastatic clear cell renal cell carcinoma (NCT00930345) – was
in phase four trial while E-PREDICT (SRCTN22979604) was in
the phase one study of the everolimus treatment before nephrec-
tomy in metastatic ccRCC. In those trials, fresh cancer tissues were
collected before and after the 6-week-long treatment. Biopsies
were taken before nephrectomy and were used as nephrectomy
samples later on. Both trials were to recruit up to 60 patients
from the discovery and validation cohorts. Treatment was stopped
2 weeks prior to nephrectomy. Responses were evaluated using the
response evaluation criteria in solid tumors (RECIST) system. The
authors claimed that the molecular genomic data may enable the
individualization of ccRCC treatment and reduce ineffective ther-
apy in drug-resistant individuals. A major focus in this project
was to put on a small hairpin RNA (shRNA). Subsequent func-
tional high-throughput small interfering RNA (siRNA) screens
were used to identify DNA/mRNA drug response biomarkers and
to point new drug targets for ccRCC. Another aim was to deter-
mine the sunitinib/everolimus acquired resistance mechanisms, as
well as the response mechanisms of these drugs in susceptible sub-
jects (96). MicroRNA expression was used as well in several other
similar research studies (105, 106).
Emerging immunotherapies for renal cell carcinoma had been
discussed by Escudier (107). Interleukin 2 (IL-2) and interferon
alpha (IFN-α) were mentioned as the first immunotherapeutics.
However, due to their high toxicity levels and the increasing evi-
dence from the novel phase I/II clinical RCC trials, it was stated that
new immunotherapies should be implemented into clinical use.
They should be able to improve the patients’ outcome in a statis-
tically significant manner. Currently, several vaccines are under
intense investigation. These include (1) AGS-003, a dendritic
cell-based vaccine, administered in combination with sunitinib
in metastatic RCC; (2) IMA901, administered with cyclophos-
phamide and developed from HLA class I and II antigens; (3)
MVA5T4, which stimulates the immune system to destroy 5T4+
cells, administered with sunitinib; and (4) autologous tumor cell
lysate therapy. The modulation of the T-cells is possible and
promising as well.
The role of immunotherapy for metastatic RCC should be
considered again, particularly the possible role of genomics
in novel immunotherapy solutions. Recent insights into the
mechanisms of immune response in RCC patients, combined
with high-throughput techniques, may allow a durable response
to immunotherapy, perhaps even avoiding the toxicity that is
usually associated with the previous types of immune treat-
ment (107, 108).
At the end of this chapter, it is emphasized that no particu-
lar targeted drug designed specifically for the treatment of renal
cell carcinoma as a result of genomic research has been accepted
for clinical practice. With regard to the obvious potential of the
genomic research, there is still more that needs to be done to imple-
ment the results mentioned above. Similarly, there is still more that
can be produced via high-throughput genomic analyses.
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CONCLUSION
Knowledge on the molecular background of renal cell carcinoma
constantly evolves due to many factors, such as the (1) advances in
high-throughput technologies; (2) better understanding of the sig-
naling and/or metabolic pathways involved in the crucial processes
and affected by specific alterations; and (3) new targeted medical
treatments (96). Genomic approaches have undoubtedly impacted
the researchers’ and clinicians’ point of view in the field of renal
cell carcinoma molecular characterization. Genome-wide stud-
ies have also provided enough data for the development of novel
therapeutics for terminally ill patients according to their specific
genotype. Still, there is more that needs to be done in this matter.
More investigations are definitely necessary to determine which
processes are critical for the induction and metastasis of kidney
cancer-specific subtypes (109, 110).
It should be noted that the Food and Drug Administration of
the US has not approved any microarrays for use in clinical prac-
tice even until now. This is due to several factors, including the
following:
1. Quality control methods, as well as methods of data interpre-
tation and analysis, have not yet been standardized. Until now,
there are no specific and widely approved protocols for use in
such studies (44).
2. There is a significant problem in the translation of genomic
data into clinical practice (111).
3. Complex biomarkers that are currently under ongoing studies
may bring both benefits and unknown risks (111).
4. Cancer heterogeneity and drug toxicity may be a specific bar-
rier for the establishment of personalized therapy in renal cell
carcinoma (95, 112).
5. Genomics-driven cancer medicine should always be rigorously
evaluated, which is not possible in all cases (50).
6. Biological pathways are not known well enough to fully pre-
dict the relations between patient’s genotype and his or her
outcome (109).
Why then is it necessary to conduct new genomic analyses
and gather more data? Novel therapies for advanced renal cell
carcinoma have substantially improved patient outcomes (113);
however, specific patients’ genetic profiles linked with personal-
ized treatment have not yet been discovered. Significant barriers
to optimal care of renal cell carcinoma (RCC) definitely exist and
those were mentioned by Rini et al. during the 2014 ASCO Gen-
itourinary Cancers Symposium (113). During the examination
and early treatment of RCC, it is basically not known whether the
patient will respond to the specific targeted therapy. In the Euro-
pean scale and, for example, American scale, where complexity
of targeted drugs implemented into practice is noticeable, there
are many targeted drugs to choose from. The decision on which
drug to choose is quite difficult as patients present different clinical
benefit and have specific tolerance to, for example, targeted agents;
up to date, the choice of therapy for an individual patient remains
empiric (114). Moreover, targeted drugs have been found to be cor-
related with specific adverse effects. Some of them are known – for
example in the case of sunitinib,which is a tyrosine kinase inhibitor
(TKI) used for the treatment of RCC and gastrointestinal stromal
tumor (GIST). It was reported that sunitinib is responsible for
cutaneous adverse effects, such as hand-foot skin reaction (HFSR)
in RCC and GIST patients (115). Still, many drug intake-adverse
effect mechanisms remain elusive and genomic research may shed
new light upon molecular biologists and oncologists knowledge in
this field. Now, their main goal is to achieve a long-term phase of
treatment benefit. To achieve prolonged survival, one has to keep
in mind that again, despite obvious successes in RCC treatment, a
number of patients still do not benefit from the therapy. Finding
specific mutations which lead to adequate adverse effects in RCC
patient is another obstacle and the reason for future research as
well (87, 111).
There are improvements necessary to be made in other areas.
For example, with regard to the patients’ survival, epidemiologic
studies are also significant for genomic research acceleration (111).
Here significant studies have been conducted – by Escudier et al.
(116), Choueiri et al. (117), or Krabbe et al. (118).
Bioinformatic analyses need to be improved as well as current
molecular biologists and biotechnologists are facing the problem
on the management of individualized RCC genomic data. There
are some useful databases available, such as My Cancer Genome;
however, most of them are still under investigation (such as Col-
labrX or GeneInsight). With regard to hotspots – places with
higher frequency of mutations – such databases are useful, but
they still have to be upgraded with regard to the possibilities of
combining data with treatment possibilities (119, 120).
Recent advances in the “-omics” era have shed new light for
future clinical practice, prevention, detailed RCC classification,
prognostic, and predictive markers development. New tools in
genomics are slowly but constantly making it more possible to
achieve. Large-scale genotyping, sequencing, and genome arrays
also have a significant impact in studies concerning cancer tissues
after nephrectomy or germ cells studies, not only on those con-
ducted on stable cancerous cell lines. Some important successes
in the field of genomic sciences in RCC genetic background have
been reached (121, 122). For example, in the genome-wide associa-
tion study (GWAS), Stadler et al. discovered RCC genetic variants
in relation to its etiology (123). It is worth noticing that a few
genome-based laboratory tests are already available (they mostly
concern personal genome profiles) (110). More than 250 new tests
were under investigation in 2010 (122).
It should be remembered that new technologies, such as next-
generation sequencing (NGS), have enabled the systematic cata-
loging of RCC genomes, a crucial step needed to achieve the goal of
overcoming the lack of clinical genomic applications. The first step
is to relevantly assess clinical utility and validity. The second is to
regard both not only in terms of hardware or software, but also in
terms of the entire process of laboratory practice. The third is PFS
(123). It is extremely crucial to educate healthcare professionals
about genomics and its potential (124).
The challenge of discovering and subsequently implementing
reliable RCC biomarkers are indisputable. Technical improve-
ments in genomics have made the research easier despite the
mentioned issues. For instance, a high-throughput sequencing
technology is more cost-effective compared to other methods.
On the other hand, sequencing the whole genome of germline
DNA allows the identification of rare high-risk alleles for renal
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cell carcinoma (125). Studying such mutations in RCC may be
possible in the future, especially if the multicenter networks of
the patients’ molecular characterization are established. Such net-
work has been created so far for lung cancer and is called the
Lung Cancer Mutation Consortium (125, 126). Various methods
of gathering new evidence in personalized medicine should lead
to the building of a specific bridge between molecular laboratory
and the clinic. This is possible to implement through the Rapid
Learning Health Care (RLHC) model, which is very promising
and is one of the key factors that can enable personalized genomic
medical care (127, 128).
Each subtype of renal cell carcinoma, as well as its clear cell
subtype, presents distinctive molecular and clinical features with
unique tumor biology, patient prognosis, and patient’s response to
treatment. With the new profiling techniques, we may now be able
to analyze significant amounts of candidate genes not only to iden-
tify RCC subtypes, but also to improve prognostic and predictive
information for patients and clinicians (94). Such research tools
usage has been presented for example during the 2013 ASCO Gen-
itourinary Cancers Symposium by Hakimi et al., who showed that
microRNA may serve as novel blood-based biomarker in ccRCC
diagnostic process (129). On the other hand, Luis M. Antón Apari-
cio et al. have presented their research project comprising mole-
cular expression profiling and pathway analysis of formalin-fixed
paraffin-embedded primary renal tumor specimens (130). Finally,
also Hakimi’s research team has shown that the analysis of the
Cancer Genome Atlas Project Association enables to gather a sig-
nificant amount of information, in this case it were mutations in,
previously mentioned in the article, chromatin modifiers, which
positively correlated with poor survival in ccRCC (131). In fact,
it has been suggested by Jones et al. that genomic research may
provide information regarding the early stage changes in the gene
expression in ccRCC, which may open the window for targeted
therapy (111); especially that ccRCC is usually associated with
the worst prognosis among other renal cancer subtypes. Unfor-
tunately, none of the microarray data published clearly and fully
identified the different panels of genes specific for each RCC stage.
This may change in the future, though, if a team-based science,
such as networks and consortia, would be applied. Combining
knowledge obtained from different fields may lead to scientific
improvements in personalized treatment in general (132).
In summary, it may be asked whether genomics could really
serve as the first step toward personalized treatment in renal cell
carcinoma. Fortunately, some studies conducted are repeatable
(14, 101, 102) and have some considerable potential for the imple-
mentation of genomic research into clinical studies. There are no
other techniques that can enable us to gather a huge amount of
data than high-throughput analyses. The most important obsta-
cle to overcome is adjusting to worldwide protocols, as a result
of extended interdisciplinary teamwork, to transform those data
into clinical practice (19). High-throughput research has one of
the highest scientific potential that may be implemented into the
research on renal cell carcinoma and this deduction is widely
supported (19, 125–128).
Implementing personalized treatment is challenging not only in
the field of renal cell carcinoma but also in the case of many other
types of tumors; such approach would definitely require better
understanding of cancer genomics and high-throughout meth-
ods at the same time. Understanding complex data sets obtained
nowadays in huge amounts will be also necessary to achieve results
in personalized care. From the molecular point of view, it is cru-
cial that clinicians cooperate properly with molecular biologists or
medical biotechnologists (or similar) in order to fully understand
the issue of targeted drugs. The most appealing problem and there-
fore a challenge is obtaining such drugs and/or molecular markers
based on the genomic profile of a patient’s tumor (133). It has
to be clearly stated again that this issue concerns many cancer
types; basically in most of them, genomic research have been con-
ducted to seek for the opportunities of personalized care. Most
up-to-date publications in PubMed in the field of cancer research
with the use of genomic techniques include, i.e., RCC (134), lung
cancer (135), hepatocellular carcinoma (136), breast cancer (137),
colorectal cancer (138), leukemia (139), prostate cancer (140), etc.
or complex studies (132, 141).
As it was stated by Renato Dulbecco, a co-recipient of the Nobel
Prize in 1975, “the time has come to obtain a truly comprehen-
sive catalog of genes involved in cancer, bringing to bear all the
power of new tools of genomics and molecular biology to the
problem” (142).
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